Objective To evaluate maternal and perinatal outcomes after induction of labour versus expectant management in pregnant women with gestational diabetes at term.
Introduction
Gestational diabetes mellitus (GDM) is defined as 'any degree of glucose intolerance with onset or first recognition during pregnancy', excluding women diagnosed with overt diabetes by standard criteria at their initial prenatal visits. [1] [2] [3] Evidence indicates that GDM exposes patients to a higher risk of obstetrical complications. 4, 5 A continuous relationship between maternal hyperglycaemia and adverse perinatal outcomes has been demonstrated. [6] [7] [8] Maternal GDM provokes an increased incidence of fetal macrosomia, shoulder dystocia, and related morbidity. 9, 10 Operative ClinicalTrials.gov number: NCT01058772
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vaginal delivery was identified as an additional risk factor for the development of shoulder dystocia.
11
The timing and mode of delivery in GDM patients remains controversial. 12, 13 Both the American College of Obstetricians and Gynecologists and the Royal College of Obstetricians and Gynaecologists state that it is reasonable to offer an elective caesarean to patients with GDM whose estimated fetal weight is 4500 g or greater.
14, 15 The Australasian Diabetes in Pregnancy Society suggests a fetal weight of 4250-4500 g as an appropriate cut-off point to offer an elective caesarean delivery. 16 In the UK, the National Institute for Health and Care Excellence (NICE) stated that there is evidence to suggest that induction of labour prior to 40 weeks of gestation may reduce the risk of shoulder dystocia. 6 Some evidence suggests an increased risk of stillbirth among women affected by GDM at term. 17 The risks of expectant management are similar to the risk of delivery at 37 weeks of gestation, but exceeded that risk at 38 weeks of gestation and beyond. 17 A planned early delivery versus expectant management for a suspected compromised fetus at term did not demonstrate any differences in neonatal morbidity and neurodevelopmental outcomes. 18 Induction of labour at 38-39 weeks of gestation could prevent some unpredictable fetal deaths without affecting neonatal neurodevelopment, however.
On the other hand, induction of labour in patients with GDM has been related to increased risks of caesarean section, especially in nulliparous women, 19, 20 and admission to the neonatal intensive care unit. 21 To the best of our knowledge only one randomised clinical trial (RCT) has been included in the reviews investigating this issue, 12, 13 and it included women affected by both gestational and overt diabetes. 22 In addition, a few non-randomised clinical trials and observational studies have been published with obvious methodological limitations. [23] [24] [25] [26] [27] [28] [29] The guidelines currently in use are mainly based on retrospective studies, and there is no consensus on the clinical management of these women. 30 We conducted a multicentre RCT to evaluate maternal and neonatal outcomes in GDM pregnancies managed actively or expectantly.
Methods
A multicentre open-label RCT was carried out. Randomisation was centralised and coordinated by the Clinical Epidemiology and Biostatistics Unit (IRCCS Burlo Garofolo) using a computer-based method. The randomisation list was blocked and stratified by centre. The allocation concealment was guaranteed through the use of consecutively numbered and sealed opaque envelopes. The study was an open-label trial because of the practical impossibility to blind either healthcare professionals or patients to the allocation group.
The Ethical Review Board at each participating centre approved the study protocol. Patients were not involved in the design of the study but participated in the Ethical Committee at IRCCS Burlo Garofolo to approve the final study protocol. Both study interventions have been largely used in the clinical context as normal practice to manage patients affected by gestational diabetes. Serious adverse outcomes were evaluated by an independent Data Monitoring Committee. Before starting the recruitment, the trial was submitted to ClinicalTrials.gov (NCT01058772) for prospective registration.
After comprehensive discussion, all participants gave written informed consent. The study methods have been published elsewhere. 30 A brief overview is presented here. Patients older than 18 years of age, with a singleton pregnancy, vertex presentation, and diagnosed with GDM in their current pregnancy were invited to participate. Exclusion criteria were a diagnosis of overt diabetes, prior caesarean section, obstetrical contraindications to vaginal delivery, maternal pregnancy-related disease or non-reassuring fetal wellbeing necessitating prompt delivery, uncertain gestational age, known fetal anomaly, a Bishop score of >7, or an estimated fetal weight of >4000 g at enrolment. In fact, a Bishop score of >7 could increase the chances of a successful induction of labour, possibly affecting the results. An estimated fetal weight of >4000 g between 38 +0 and 39 +0 weeks of gestation could easily develop into a case of macrosomia from 40 weeks of gestation onwards.
The diagnosis of GDM was based on the International Association of Diabetes and Pregnancy Study Groups criteria (IADPSGC), and the available Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study results, adapted by means of the standard practice at each centre. 1 Before the consensus was published some centres adopted Carpenter and Coustan criteria, according to the study protocol. 30 Table 1 shows the percentage of women screened by IADPSGC criteria. Patients with a mean blood glucose level equal to or less than 95 mg/dl were considered well controlled, and those with a mean blood glucose level of >95 mg/dl were considered poorly controlled.
Eligible patients were enrolled between 38 +0 and 39 +0 weeks of gestation, verified by last menstrual period and confirmed by the first-trimester sonographic measurement of crown-rump length. On the day of enrolment, both an ultrasound assessment of fetal weight and a Bishop score evaluation were performed. Whenever the estimated fetal weight exceeded 4000 g, patients were considered not eligible and were offered a caesarean section. Furthermore, a careful evaluation of possible contraindications to vaginal delivery and an assessment of fetal wellbeing through a cardiotocographic trace were carried out. In the case of suspected fetal distress, a biophysical profile was carried out and patients were managed accordingly. The remaining inclusion/exclusion criteria were assessed through the evaluation of the patient's actual history and an examination of the patient.
Patients assigned to induction of labour were admitted to the ward and induction was performed. More details about modalities of induction are available in the published protocol. 30 Patients enrolled in the conservatively managed group were followed up twice-weekly by electronic fetal heart rate monitoring and biophysical profile until 41 +0 weeks of gestation, when induction of labour was then offered. Data were recorded in an appropriate paper questionnaire in the first instance, and then reported on an electronic database accessible from different study sites.
The main study outcome was the incidence of caesarean section among women undergoing induction of labour and among women assigned to expectant management. Furthermore, we decided to assess the incidence of non-spontaneous delivery as a relevant outcome (i.e. caesarean section plus operative vaginal deliveries), which was not included in the statistical analysis plan initially. The study group evaluated that operative vaginal delivery should be assessed because it is a recognised risk factor for shoulder dystocia and other related possible outcomes.
11 Secondary outcomes were assessed at the time of delivery and/or during maternal and neonatal admission until discharge. Maternal and neonatal outcomes evaluated at delivery were: mode of delivery, spontaneous or assisted third stage of labour, perineal tears, postpartum haemorrhage, gestational age and weight at birth, shoulder dystocia, neonatal respiratory distress, Apgar score, and arterial cord pH. The remaining secondary outcomes were recorded until discharge [maternal blood transfusion, intensive care unit (ICU) admission, hypoglycaemia in the newborn, neonatal intensive care unit (NICU) admission, maternal and perinatal death].
Hypoglycaemia was diagnosed by two consecutive values of plasma glucose equal to or less than 40 mg/dl. 8 Hyperbilirubinaemia was defined by plasma values >12 mg/dl or by evidence of phototherapy treatment after birth. 8 The sample size to achieve significant results concerning the primary outcome was initially estimated as 1760 patients (n = 880 per intervention group), given an expected caesarean section frequency of 31% in the expectant group and 25% in the induction group, with an a error equal to 5% and an 80% power. The obvious obstacles to recruiting pregnant women at such a delicate moment were evident during the recruitment phase, and thus the time period was much extended compared with the original plan. The GINEXMAL study group agreed to conclude the recruitment phase after 4 years, despite not achieving the planned sample size.
Data were analysed by 'intention to treat' using the STATA 11 statistical package (StataCorp LP, College Station, TX, USA). Continuous variables were reported as means and standard deviations (SDs), and categorical variables were reported as proportions and percentages. The two groups were compared by their main characteristics to evaluate the efficacy of the randomisation process. Primary and secondary outcomes comparing the two arms were evaluated by carrying out v 2 or Fisher's exact tests. Statistically significant differences were determined by P < 0.05.
To evaluate the possible effects of policy at the participating centres, and to assess whether delivering at a specific recruiting centre had an impact on study outcomes, a mixed-effects logistic regression with a random factor for centre was carried out.
Finally, a sensitivity analysis for the primary outcome was performed to confirm that our results did not change despite crossovers between arms.
Results
Between March 2010 and March 2014 the GINEXMAL group recruited 530 women affected by GDM at eight different centres in Italy, Slovenia, and Israel. Among them, 59 women opted out and 46 women were not eligible (Figure 1) .
Out of 425 patients, 214 were randomised to induction of labour and 211 were randomised to expectant management. Although there were crossovers between the two allocation groups, the women in each group were numerically balanced ( Figure 1) . Furthermore, the analysis was carried out by 'intention to treat'. Table 1 presents the maternal characteristics of women randomised into the two study arms. There were no clinically relevant differences between the two groups for the variables considered, except for GDM treatment (Table 1) . There were no differences in the percentage of wellcontrolled GDM cases between the two randomisation groups (induction 88.7% versus expectant 90.9%).
Gestational diabetes mellitus (GDM) was diagnosed by the HAPO study criteria in 77.7% of patients in both arms. There was no significant difference between the two groups in terms of estimated fetal weight at the ultrasound scans performed upon enrolment (Table 1) . Among women assigned to induction, two presented with spontaneous onset of labour and consequently delivered. In the expectant arm, 50 patients underwent induction of labour during follow-up for obstetrical or medical indications (Figure 1) . The most common causes were post-term pregnancy (26.5%), premature rupture of membranes (32.7%), and fetal distress (16.3%).
As expected from the nature of the intervention, neonates in the induction group were born earlier (74.4% in the expectant group were born later than 39 weeks of gestation, versus 22.0% in the induction group; relative risk, RR 0.30; 95% confidence interval, 95% CI 0.23-0.38; P < 0.001) and accordingly weighed less (mean 3218.6 g; SD 426.7 g) than neonates in the expectant group (mean 3396.9 g; SD 487.3 g; P < 0.001).
The incidence of caesarean section was 12.6% among women randomised to induction of labour and 11.8% among women randomised to expectant management ( Table 2 ). The RR of delivery by caesarean section in the induction group versus expectant group was 1.06 (95% CI 0.64-1.77; P = 0.81). Sensitivity analysis carried out 'as treated' did not change the results (RR 1.27; 95% CI 0.76-2.12; P = 0.36). The most common indications for caesarean section were non-reassuring fetal heart monitoring (expectant 48% versus induction 25%), mechanical dystocia, defined as fetopelvic disproportion (expectant 20% versus induction 33%), and dynamic dystocia, defined as inadequate cervical dilation or fetal descent (expectant 12% versus induction 29.6%). The RR of non-spontaneous delivery (i.e. caesarean section or operative vaginal delivery) in the induction group versus expectant group was 0.94 (95% CI 0.66-1.36; P = 0.76). Sensitivity analysis carried out 'as treated' confirmed the 'intention to treat' results (RR 0.92; 95% CI 0.64-1.32; P = 0.65). Adding a random factor for centre to the analysis did not modify the relationship between intervention and outcome.
No maternal or perinatal deaths occurred. No significant difference was found in terms of postpartum haemorrhage, severe perineal tears, maternal blood transfusion, management of third stage of labour, and ICU admission (Table 3) . Among neonatal outcomes, a difference was identified only with regards to neonatal hyperbilirubinaemia (Table 4 ). The RR of developing hyperbilirubinaemia among neonates born in the induction group was two-fold greater compared with neonates in the expectant group (RR 2.46; 95% CI 1.11-5.46; P = 0.03). The RR of neonatal macrosomia (defined as birthweight ≥4000 g), 11 comparing the induction group with the expectant group, Table S1 .
Discussion

Main findings
The main study outcome was the incidence of caesarean section, which was low in both study arms (induction group, 12.6%; expectant group, 11.8%). No difference was detected between the two arms both in caesarean section rate and in non-spontaneous delivery rate (either operative delivery or caesarean section). The relationship between intervention and outcome did not change after adjusting by recruiting centre. Maternal and neonatal outcomes were similar in the two groups except for hyperbilirubinaemia in the neonate. As expected, gestational age and birthweight were lower in the induction group. A few cases of shoulder dystocia occurred and were solved without significant birth trauma.
Strengths and limitations
The main limitation of our study was ending the recruitment phase without achieving the planned sample size. Recruiting women in an obstetrics context has been reported as being very difficult. 31 In fact, in this context, the idea of being randomized to a group, so that chance would decide instead of an informed women' decision or a rational professionals' decision based on skills and experience, is very difficult to accept. 31 Although our study is the largest published focusing on this issue, it resulted underpowered, and so we may have failed to detect an effect or an association that does exist (a false-negative result). Confidence intervals show a wide range of possible results, from a protective effect of induction of 34% to an increased risk of 77%, making it impossible to draw definitive conclusions; however, the very small difference between the two groups is consistent, regardless of the analysis performed ('intention to treat' versus 'as treated') and adjustment by centre. It was achieved in a relatively high number of women, making it unlikely that the result would change by increasing the sample size.
Another limitation of our study is associated with the possible risk of selection bias. Women with GDM offered entry to the study were fewer in number than those followed-up by recruiting centres during the study period. This could be explained by the pragmatic nature of our trial, carried out in a real-life setting. This could have led to the recruitment of a patient being missed for motivational reasons, organisational issues, or a lack of time. In any case, we truly think that the percentage of missing patients was the result of chance. In fact, our population was similar to a low-risk population affected by GDM in Europe. 32 Furthermore, crossovers between the two study arms could limit our results. A sensitivity analysis was carried out and no differences were observed when data were analysed by 'intention to treat' versus 'as treated'. Finally, in our study the two arms were unbalanced for GDM treatment during pregnancy. Women in the induction group received more insulin and glyburide compared with women in the expectant group. This finding could indicate a different severity of disease, and could consequently affect the results. Given that the number of women with well-controlled GDM was well balanced between the two groups, we believe that it did not affect the study results.
Strengths of our trial include the randomised design and the use of central randomisation. Furthermore, to our knowledge this is the first multicentre randomised trial focusing on women affected exclusively by GDM, and the largest carried out so far.
Interpretation
In our study the incidence of caesarean section was generally lower than what is reported in the literature. A recent study analysing pregnancy outcomes of women diagnosed with GDM by IADPSGC reported an incidence of caesarean section equal to 19.7%. 33 Our finding of a lower incidence could be explained by the exclusion criteria applied. In fact, major risk factors for caesarean section, such as maternal diseases, previous caesarean section, fetal distress, or estimated fetal weight equal or greater than 4000 g would have excluded a patient from randomisation. This could have selected a population exposed to a general lower risk of caesarean section, despite the diagnosis of GDM. In addition, the majority of randomised women were characterised by a healthy body mass index (BMI). The percentage of obese women, defined as a BMI of ≥30 kg/m 2 , was about 14% in our sample. About 22% of overweight women were identified (with BMIs of between 25 and 29 kg/m 2 ). Given that the risk of caesarean section among women who are obese, compared with women of healthy weight, is estimated as being 2.1-fold higher, 32 the relatively low percentage of women who are obese in our sample could offer another explanation to our general low incidence of caesarean section. Finally, the low rate of caesarean section could be explained by the Hawthorne effect. It is reported in the literature that better outcomes could be related to carrying out a randomised trial: better outcomes could be more frequent in populations entered into trials than in those receiving standard care. 34 Concerning the reasons of the relatively low incidence of obesity, a possible explanation can be found in the exclusion criteria applied to select patients. Patients that are obese are more likely to develop maternal diseases such as hypertensive disorders as well as being affected by birth defects, 32 conditions that would have excluded patients from randomisation in the first instance. Similar values of maternal BMI were reported in a recent trial comparing induction of labour versus expectant management in largefor-date fetuses and in other previous published works in the European context. 35, 36 The management of GDM pregnancies at term has been debated for years. 6 The rationale behind the induction of labour at 38-39 weeks of gestation concerns the reduction in the birthweights of newborns, and thus a putative decreased risk of adverse neonatal outcomes. 6 Active management obviously reduced the birthweights of newborns in our sample, but did not reduce the incidence of shoulder dystocia. The only previous randomised trial focusing on this issue reported a reduction in shoulder dystocia, but the women included were affected by gestational and overt diabetes. 22 Shoulder dystocia is a very rare outcome and our sample size was not designed to detect a difference in its terms. 30 In our sample shoulder dystocia occurred in 0.9% of cases: 1.4% in the induction group and 0.5% in the expectant management group. These results were in line with previous studies including newborns with similar birthweights. 37 It could be reasonable to assume that a significant difference in birthweight could reduce the risk of shoulder dystocia, 38 as recently demonstrated among largefor-date fetuses. 35 As our study was underpowered, no definitive conclusions can be drawn.
Although there is some evidence in the literature indicating the possible relationship between GDM and an increased risk of perinatal death, in our sample none occurred. 18 Previous published studies focusing on this issue were characterised by methodological limitations, 6, 18 and currently there is no convincing evidence of a true relationship between GDM and risk of intrauterine fetal death. 6 Further evidence is needed to address this issue and, until then, safer pregnancy outcomes could be achieved by delivering these babies by 40 weeks of gestation. 6 Some authors advocate an increased risk of caesarean section as the main argument against induction of labour, and support the argument for expectant management for these patients. 20 Others suggest that active management in nulliparous women, induced at 39 weeks of gestation for suspected fetal macrosomia, could reduce the incidence of caesarean section in comparison with expectant management. 8, 39 In our sample the risk of performing a caesarean section was not different between the induction group and the expectant group. When the analysis was focused on non-spontaneous delivery, no difference was identified between the two groups.
A possible association between induction of labour and an increased risk of NICU admission was recently highlighted in women with GDM, when compared with the expectant group. 21 In our sample no differences were identified between the two arms in terms of neonatal morbidity, with the exception of neonatal hyperbilirubinaemia, which was significantly associated with induction of labour, confirming previous findings. 35, 39, 40 
Conclusion
In conclusion, our results are transferable only to a comparable low-risk population, except for GDM diagnosis. In similar conditions, our results suggest no clinical difference in birth outcomes can be expected, regardless of the approach used (i.e. active versus expectant management). Although the study is underpowered, the magnitude of the between-group difference is small and without clinical relevance.
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